BioNTech SE (22UAy)

  • Get an in-depth profile of BioNTech SE, including a general overview of the company's business and key management, as well as employee data and location and contact information.

Select Exchange

Symbol Exchange Currency
BNTX NASDAQ USD Real-time BNTXN BIVA MXN Delayed 22UAy Xetra EUR Delayed 22UAy Frankfurt EUR Delayed 22UAy TradeGate EUR Delayed BNTX Vienna EUR Real-time
90.20 -4.14 (-4.39%)
Closed EUR Disclaimer

BioNTech SE Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
4530
Equity Type
DRC
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Contact Information
Address
Mainz,55131 Germany
Phone
49 6131 9084 0
Fax
49 6131 9084 390
Web
https://www.biontech.de
Top Executives
Name
Age
Since
Title
Helmut W. Jeggle 51 2008 Independent Supervisory Board Chairman
Ulrich Wandschneider 61 2018 Independent Deputy Chairman Supervisory Board
Rolf M. Zinkernagel 79 0000 Member of Scientific Advisory Board
Michael Motschmann 66 2008 Independent Supervisory Board Member
Hans Hengartner 79 0000 Member of Scientific Advisory Board
Nicola Blackwood 44 2023 Member of Supervisory Board
Anja Morawietz 46 2022 Supervisory Board Member
Rudolf Staudigl 69 2022 Supervisory Board Member

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.